Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Curasight enters clinic with uTREAT for glioblastoma, advancing dual radiopharma strategy Curasight starts first-in-human trial of uTREAT in glioblastoma, launching its therapeutic radiopharmaceutical program. Read the full strategic analysis. byVenkateshJanuary 5, 2026